Larry A Allen1, Gregg C Fonarow2, DaJuanicia N Simon3, Laine E Thomas3, Lucas N Marzec4, Sean D Pokorney3, Bernard J Gersh5, Alan S Go6, Elaine M Hylek7, Peter R Kowey8, Kenneth W Mahaffey9, Paul Chang10, Eric D Peterson3, Jonathan P Piccini3. 1. University of Colorado School of Medicine, Aurora, Colorado. Electronic address: larry.allen@ucdenver.edu. 2. University of California, Los Angeles, California. 3. Duke Clinical Research Institute, Durham, North Carolina. 4. University of Colorado School of Medicine, Aurora, Colorado. 5. Mayo Clinic College of Medicine, Rochester, Minnesota. 6. Kaiser Permanente Northern California, Oakland, California. 7. Boston University School of Medicine, Boston, Massachusetts. 8. Lankenau Heart Institute and the Jefferson Medical College, Philadelphia, Pennsylvania. 9. Stanford University School of Medicine, Palo Alto, California. 10. Janssen Scientific Affairs, Raritan, New Jersey.
Abstract
BACKGROUND: Although digoxin has long been used to treat atrial fibrillation (AF) and heart failure (HF), its safety remains controversial. OBJECTIVES: This study sought to describe digoxin use over time in patients with AF who were stratified by the presence or absence of HF, to characterize the predictors of digoxin use and initiation, and to correlate digoxin use with outcomes. METHODS: Longitudinal patterns of digoxin use and its association with a variety of outcomes were assessed in a prospective outpatient registry conducted at 174 U.S. sites with enrollment from June 2010 to August 2011. RESULTS: Among 9,619 patients with AF and serial follow-up every 6 months for up to 3 years, 2,267 (23.6%) received digoxin at study enrollment, 681 (7.1%) were initiated on digoxin during follow-up, and 6,671 (69.4%) were never prescribed digoxin. After adjusting for other medications, heart rate was 72.9 beats/min among digoxin users and 71.5 beats/min among nonusers (p < 0.0001). Prevalent digoxin use at registry enrollment was not associated with subsequent onset of symptoms, hospitalization, or mortality (in patients with HF, adjusted hazard ratio [HR] for death: 1.04; without HF, HR: 1.22). Incident digoxin use during follow-up was not associated with subsequent death in patients with HF (propensity adjusted HR: 1.05), but was associated with subsequent death in those without HF (propensity adjusted HR: 1.99). CONCLUSIONS: After adjustment for detailed clinical factors, digoxin use in registry patients with AF had a neutral association with outcomes under most circumstances. Because of the multiple conflicting observational reports about digoxin's safety and possible concerns in specific clinical situations, a large pragmatic trial of digoxin therapy in AF is needed.
BACKGROUND: Although digoxin has long been used to treat atrial fibrillation (AF) and heart failure (HF), its safety remains controversial. OBJECTIVES: This study sought to describe digoxin use over time in patients with AF who were stratified by the presence or absence of HF, to characterize the predictors of digoxin use and initiation, and to correlate digoxin use with outcomes. METHODS: Longitudinal patterns of digoxin use and its association with a variety of outcomes were assessed in a prospective outpatient registry conducted at 174 U.S. sites with enrollment from June 2010 to August 2011. RESULTS: Among 9,619 patients with AF and serial follow-up every 6 months for up to 3 years, 2,267 (23.6%) received digoxin at study enrollment, 681 (7.1%) were initiated on digoxin during follow-up, and 6,671 (69.4%) were never prescribed digoxin. After adjusting for other medications, heart rate was 72.9 beats/min among digoxin users and 71.5 beats/min among nonusers (p < 0.0001). Prevalent digoxin use at registry enrollment was not associated with subsequent onset of symptoms, hospitalization, or mortality (in patients with HF, adjusted hazard ratio [HR] for death: 1.04; without HF, HR: 1.22). Incident digoxin use during follow-up was not associated with subsequent death in patients with HF (propensity adjusted HR: 1.05), but was associated with subsequent death in those without HF (propensity adjusted HR: 1.99). CONCLUSIONS: After adjustment for detailed clinical factors, digoxin use in registry patients with AF had a neutral association with outcomes under most circumstances. Because of the multiple conflicting observational reports about digoxin's safety and possible concerns in specific clinical situations, a large pragmatic trial of digoxin therapy in AF is needed.
Authors: Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Paulus Kirchhof; Carina Blomstrom-Lundqvist; Luigi P Badano; Farid Aliyev; Dietmar Bänsch; Helmut Baumgartner; Walid Bsata; Peter Buser; Philippe Charron; Jean-Claude Daubert; Dan Dobreanu; Svein Faerestrand; David Hasdai; Arno W Hoes; Jean-Yves Le Heuzey; Hercules Mavrakis; Theresa McDonagh; Jose Luis Merino; Mostapha M Nawar; Jens Cosedis Nielsen; Burkert Pieske; Lidija Poposka; Frank Ruschitzka; Michal Tendera; Isabelle C Van Gelder; Carol M Wilson Journal: Eur Heart J Date: 2013-06-24 Impact factor: 29.983
Authors: Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Robert A Guyton; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jean-Yves Le Heuzey; G Neal Kay; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann Journal: J Am Coll Cardiol Date: 2013-04-01 Impact factor: 24.094
Authors: Jonathan P Piccini; Elizabeth S Fraulo; Jack E Ansell; Gregg C Fonarow; Bernard J Gersh; Alan S Go; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Laine E Thomas; Melissa H Kong; Renato D Lopes; Roger M Mills; Eric D Peterson Journal: Am Heart J Date: 2011-10 Impact factor: 4.749
Authors: John Spertus; Paul Dorian; Rosemary Bubien; Steve Lewis; Donna Godejohn; Matthew R Reynolds; Dhanunjaya R Lakkireddy; Alan P Wimmer; Anil Bhandari; Caroline Burk Journal: Circ Arrhythm Electrophysiol Date: 2010-12-15
Authors: Mihai Gheorghiade; Gregg C Fonarow; Dirk J van Veldhuisen; John G F Cleland; Javed Butler; Andrew E Epstein; Kanan Patel; Inmaculada B Aban; Wilbert S Aronow; Stefan D Anker; Ali Ahmed Journal: Eur Heart J Date: 2013-04-16 Impact factor: 29.983
Authors: Mihai Gheorghiade; Kanan Patel; Gerasimos Filippatos; Stefan D Anker; Dirk J van Veldhuisen; John G F Cleland; Marco Metra; Inmaculada B Aban; Stephen J Greene; Kirkwood F Adams; John J V McMurray; Ali Ahmed Journal: Eur J Heart Fail Date: 2013-01-25 Impact factor: 15.534
Authors: Matthew G Whitbeck; Richard J Charnigo; Paul Khairy; Khaled Ziada; Alison L Bailey; Milagros M Zegarra; Jignesh Shah; Gustavo Morales; Tracy Macaulay; Vincent L Sorrell; Charles L Campbell; John Gurley; Paul Anaya; Hafez Nasr; Rong Bai; Luigi Di Biase; David C Booth; Guillaume Jondeau; Andrea Natale; Denis Roy; Susan Smyth; David J Moliterno; Claude S Elayi Journal: Eur Heart J Date: 2012-11-27 Impact factor: 29.983
Authors: Surbhi Chamaria; Anand M Desai; Pratap C Reddy; Brian Olshansky; Paari Dominic Journal: Cardiol Res Pract Date: 2015-12-14 Impact factor: 1.866
Authors: Alon Eisen; Christian T Ruff; Eugene Braunwald; Francesco Nordio; Ramón Corbalán; Anthony Dalby; Maria Dorobantu; Michele Mercuri; Hans Lanz; Howard Rutman; Stephen D Wiviott; Elliott M Antman; Robert P Giugliano Journal: J Am Heart Assoc Date: 2016-07-08 Impact factor: 5.501
Authors: Oliver J Ziff; Deirdre A Lane; Monica Samra; Michael Griffith; Paulus Kirchhof; Gregory Y H Lip; Richard P Steeds; Jonathan Townend; Dipak Kotecha Journal: BMJ Date: 2015-08-30